Alliance Global Partners raised the firm’s price target on Aspira Women’s Health to $7.20 from $5.65 and keeps a Buy rating on the shares following the investor day. The increase stems from a boost in the stock’s valuation multiple reflecting an improved balance sheet and “catalyst-rich” upcoming calendar, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AWH:
- Aspira Women’s Health Adjusts Warrant Terms Post-Split
- Aspira Women’s Health Executes Private Equity Placement
- Aspira Women’s Health Announces New Securities Offering Deal
- Aspira Women’s Health announces $5.5M registered direct offering
- Aspira Women’s Health to hold a virtual research and development day
